Dexamethasone/netilmicin - SIFI

Drug Profile

Dexamethasone/netilmicin - SIFI

Alternative Names: Dexamethasone/netilmicin; Netildex; Netilmicin/dexamethasone

Latest Information Update: 19 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SIFI
  • Developer Knight Therapeutics; SIFI
  • Class Aminoglycosides; Anti-infectives; Anti-inflammatories; Antibacterials; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids
  • Mechanism of Action Arachidonic acid inhibitors; Bacterial protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation

Most Recent Events

  • 15 Feb 2018 Preregistration for Ocular inflammation in Canada (Ophthalmic, Drops)
  • 15 Feb 2018 Health Canada accepts New Drug Submission for Dexamethasone/netilmicin for Ocular inflammation for review
  • 22 Nov 2016 SIFI and Sintesi Research Srl plan a phase III trial for Ocular inflammation associated with cataract extraction in Italy, Germany and Romania (Ophthalmic, Gel) (NCT02973880)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top